What are the guidelines on discontinuing DMAMS in the treatment of multiple sclerosis (MS)?

Updated: Oct 08, 2019
  • Author: Christopher Luzzio, MD; Chief Editor: Jasvinder Chawla, MD, MBA  more...
  • Print

The guidelines further recommend that treatment with any disease-modifying medication should be continued indefinitely, unless any of the following occur:

  • The patient or healthcare provider determines that the treatment is failing to adequately control the disease
  • The side effects are intolerable
  • The patient is unable to follow the recommended treatment regimen
  • A more appropriate treatment becomes available

Additional recommendations include the following:

  • Switch from one disease-modifying treatment to another should only occur for medically appropriate reasons
  • When a medication is not providing adequate benefit, another agent with a different mechanism of action should be considered
  • Factors affecting choice of treatment are complex and should be addressed collaboratively by the patient and healthcare provider
  • Access to treatment should not be limited by frequency of relapses, level of disability, or personal characteristics such as age, gender, or ethnicity
  • Absence of relapses may indicate that the treatment is working and should not be considered a justification for discontinuing the treatment

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!